Fieldpoint Private Securities’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
$79K Sell
280
-25
-8% -$6.69K 0.02% 404
2022
Q1
$80K Buy
305
+20
+7% +$4.75K 0.02% 473
2021
Q4
$63K Buy
285
+260
+1,040% +$50.6K 0.01% 545
2021
Q3
$5K Hold
25
﹤0.01% 1283
2021
Q2
$5K Sell
25
-22
-47% -$4.6K ﹤0.01% 1232
2021
Q1
$10K Sell
47
-222
-83% -$48.8K ﹤0.01% 1009
2020
Q4
$64K Buy
+269
New +$61.7K 0.01% 449

Other funds holding VRTX

Fieldpoint Private Securities's VRTX Position: Q2 2022 in Review

Fieldpoint Private Securities reduced its Vertex Pharmaceuticals (VRTX) stake by 8.2% in Q2 2022, selling an estimated $6.69K and leaving 280 shares worth $79K. The position accounts for 0.02% of the portfolio, ranked #404.

Fieldpoint Private Securities first reported a position in VRTX in Q4 2020 and has held it in 7 quarters since. The position peaked at $80K in Q1 2022. 1,107 funds tracked by Wall St. Rank hold VRTX as of Q2 2022.

  • Fieldpoint Private Securities held 280 shares of Vertex Pharmaceuticals worth $79K as of Q2 2022.
  • Fieldpoint Private Securities sold 25 Vertex Pharmaceuticals shares in Q2 2022, an estimated $6.69K.
  • Vertex Pharmaceuticals made up 0.02% of Fieldpoint Private Securities's portfolio in Q2 2022, its #404 holding.
  • Fieldpoint Private Securities first reported a position in Vertex Pharmaceuticals in Q4 2020 and has held it in 7 quarters since.
  • Fieldpoint Private Securities's Vertex Pharmaceuticals position peaked at $80K in Q1 2022.
  • 1,107 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2022.

Based on Fieldpoint Private Securities's 13F filing for Q2 2022, filed 5 Aug 2022.